F. Castinetti

Management of Aggressive PitNETs: Evidence Gaps, Molecular Clues, and a Roadmap for Clinical Trials.

Aggressive and metastatic pituitary neuroendocrine tumors constitute a rare yet biologically distinct group of lesions, marked by rapid growth, therapeutic resistance, and unpredictable clinical behavior. Despite their rarity, they contribute disproportionately to morbidity due to the absence of reliable prognostic and...